Mistletoe (Viscum album)

European white mistletoe — most widely used complementary cancer therapy in Central Europe

Key Points

• Mistletoe extracts (Iscador, Helixor, Abnoba Viscum) contain lectins (ML-I, II, III) and viscotoxins with immunomodulatory and cytotoxic properties.
• European meta-analyses show consistent improvements in quality of life, fatigue, and treatment tolerability across breast, lung, colorectal, and pancreatic cancers.
• The 2023 MISTLETOE-2 Phase IIa trial demonstrated acceptable safety and preliminary efficacy signals when combined with pembrolizumab.
• Survival benefit remains unproven in high-quality RCTs; most positive studies have methodological limitations.
• Administered subcutaneously 2–3×/week; local injection site reactions (redness, swelling) are common and are considered a marker of immune activation.
• Mistletoe should not be injected intravenously due to severe anaphylaxis risk; subcutaneous route is standard.

Background and Active Constituents

Viscum album (European white mistletoe), a semi-parasitic plant that grows on various deciduous trees, has been used in cancer care since Rudolf Steiner introduced anthroposophical medicine in the 1920s. Commercial preparations (Iscador, Helixor, Abnoba Viscum, Eurixor) are aqueous extracts standardized to mistletoe lectin (ML) content, with host tree species (oak, apple, pine, fir, etc.) defining extract characteristics. The biologically active components include: - **Mistletoe lectins (ML-I, ML-II, ML-III):** Ribosome-inactivating proteins that inhibit protein synthesis and induce…

Clinical Evidence

Mistletoe is one of the most extensively studied complementary oncology therapies, with over 100 clinical trials published. Evidence is strongest for quality-of-life improvement and weakest for direct anti-tumor effects. **Quality of Life:** A 2020 systematic review and meta-analysis (Freuding et al., BMC Complementary Medicine) of 26 RCTs found consistent, statistically significant improvements in QoL measures — particularly fatigue, nausea, emotional function, and overall wellbeing — across breast, colorectal, lung, and pancreatic cancers when mistletoe was added to standard care. Effect…

Administration and Dosing

Mistletoe is administered subcutaneously, typically starting at low doses (1 mg) with gradual titration to 5–20 mg (or higher in advanced protocols), given 2–3 times per week. Dose titration is guided by local injection site reactions — a red, warm, well-defined wheal of 5–10 cm diameter at the injection site is considered evidence of appropriate immune activation. Injection sites are rotated (abdomen, thigh, upper arm). Patients or caregivers are typically trained to self-inject at home after initial supervision. Local skin reactions appearing within 24 hours and resolving within 48 hours…